These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12523198)

  • 21. [Drug control within the EEC II: good possibilities for Sweden].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
    [No Abstract]   [Full Text] [Related]  

  • 22. A prescription for better prescriptions.
    Woosley RL
    Issues Sci Technol; 1994; 10(3):59-66. PubMed ID: 10133487
    [No Abstract]   [Full Text] [Related]  

  • 23. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 24. [Drug advertising--users want information. Report of telephone survey conducted by North-Rhine Westphalia Public Health Service on the topic of drug advertising and drug information for users].
    Puteanus U
    Gesundheitswesen; 2000 Oct; 62(10):516-24. PubMed ID: 11103563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secrecy and the health protection branch.
    Lexchin J
    CMAJ; 1998 Sep; 159(5):481-3. PubMed ID: 9757171
    [No Abstract]   [Full Text] [Related]  

  • 26. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 27. [The fight for existence].
    Haug C
    Tidsskr Nor Laegeforen; 2003 Jun; 123(13-14):1817. PubMed ID: 12830248
    [No Abstract]   [Full Text] [Related]  

  • 28. [Physicians report verbal drug information. Cases scrutinized by the IGM].
    Perman E
    Lakartidningen; 2004 Aug; 101(35):2648, 2650. PubMed ID: 15458219
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacological information and the drug industry. The role of its medical departments].
    Castillo Pérez P
    Med Clin (Barc); 1987 Sep; 89(7):288-95. PubMed ID: 3316871
    [No Abstract]   [Full Text] [Related]  

  • 30. Comment: the economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?
    Rosenthal M
    J Health Serv Res Policy; 2004 Jan; 9(1):39-42; discussion 41-2. PubMed ID: 15006239
    [No Abstract]   [Full Text] [Related]  

  • 31. Advertising medicines to the public.
    George CF
    J R Coll Physicians Lond; 1996; 30(2):102-3. PubMed ID: 8709051
    [No Abstract]   [Full Text] [Related]  

  • 32. [Is household-targeted Gardasil advertising in accordance with the intentions of the legislators?].
    Linnersten L
    Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2121. PubMed ID: 18751457
    [No Abstract]   [Full Text] [Related]  

  • 33. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 34. [One year's written drug information to a general practitioner].
    Molaug PO; Spigset O
    Tidsskr Nor Laegeforen; 2001 Feb; 121(5):585-8. PubMed ID: 11301615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Information or advertising?
    Coulter A
    Health Expect; 2001 Dec; 4(4):203-4. PubMed ID: 11703492
    [No Abstract]   [Full Text] [Related]  

  • 36. Availability of paediatric information in European Medicines Agency approvals.
    Hwang TJ; Tomasi PA; Saint-Raymond A; Bourgeois FT
    Lancet Child Adolesc Health; 2018 May; 2(5):e9. PubMed ID: 30169272
    [No Abstract]   [Full Text] [Related]  

  • 37. Secrecy and transparency of medicines licensing in the EU.
    Abraham J; Lewis G
    Lancet; 1998 Aug; 352(9126):480-2. PubMed ID: 9708771
    [No Abstract]   [Full Text] [Related]  

  • 38. A look back at 2000: overabundance and deregulation.
    Prescrire Int; 2001 Apr; 10(52):52-4. PubMed ID: 11718161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 40. Information from drug companies and opinion leaders.
    Liberati A; Magrini N
    BMJ; 2003 May; 326(7400):1156-7. PubMed ID: 12775588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.